|

sparsentan Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Brigham and Women's Hospital1

Indications

  • Proteinuria in Nephrotic Range1
  • Proteinuric Kidney Disease1
  • Proteinuric Renal Disease1
  • Proteinuria1
  • Cancer1

Boston, Massachusetts1 trial

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Brigham and Women's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.